BRPI0507182A - uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados - Google Patents

uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados

Info

Publication number
BRPI0507182A
BRPI0507182A BRPI0507182-8A BRPI0507182A BRPI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A BR PI0507182 A BRPI0507182 A BR PI0507182A
Authority
BR
Brazil
Prior art keywords
organo
injured
inhibitor
monomethylsilanetriol
glycoproteins
Prior art date
Application number
BRPI0507182-8A
Other languages
English (en)
Inventor
Marie-Christine Seguin
Yann Courbebaisse
Original Assignee
Exsymol Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exsymol Sa filed Critical Exsymol Sa
Publication of BRPI0507182A publication Critical patent/BRPI0507182A/pt
Publication of BRPI0507182B1 publication Critical patent/BRPI0507182B1/pt
Publication of BRPI0507182B8 publication Critical patent/BRPI0507182B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE COMPOSTOS ORGANO-SILICADOS PARA RESTRINGIR OS TECIDOS CONJUNTIVOS LESADOS. A presente invenção se refere ao uso de compostos organo-silicados representado pela fórmula geral (I) a seguir: No qual R e x são conforme definidos na descrição, os ditos compostos organo-silicados sendo estabilizados por um composto orgânico portador de uma ou de várias funções álcool, fenol, ácido, amina ou aminoácido, para restringir a organização das fibras protéicas e glicoprotéicas da matriz extracelular dos tecidos conjuntivos lesados.
BRPI0507182A 2004-02-05 2005-02-03 uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados BRPI0507182B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401095A FR2865935B1 (fr) 2004-02-05 2004-02-05 Utilisation de composes organo-silicies pour contraindre des tissus conjonctifs leses par l'intermediaire d'une action mecanique
PCT/FR2005/000229 WO2005082421A1 (fr) 2004-02-05 2005-02-03 Utilisation de composes organo-silicies pour contraindre des tissus conjonctifs leses

Publications (3)

Publication Number Publication Date
BRPI0507182A true BRPI0507182A (pt) 2007-06-26
BRPI0507182B1 BRPI0507182B1 (pt) 2019-01-29
BRPI0507182B8 BRPI0507182B8 (pt) 2021-07-27

Family

ID=34778526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507182A BRPI0507182B8 (pt) 2004-02-05 2005-02-03 uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados

Country Status (11)

Country Link
EP (1) EP1750770B1 (pt)
KR (1) KR101162389B1 (pt)
CN (1) CN1917904B (pt)
AT (1) ATE537846T1 (pt)
BR (1) BRPI0507182B8 (pt)
ES (1) ES2377750T3 (pt)
FR (1) FR2865935B1 (pt)
MX (1) MXPA06008898A (pt)
PL (1) PL1750770T3 (pt)
PT (1) PT1750770E (pt)
WO (1) WO2005082421A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2936708B1 (fr) 2008-10-03 2012-08-17 Exsymol Sa Complexe associant un derive organique du silicium avec des fragments calibres d'acide hyaluronique, a action preventive et reparatrice des degradations cutanees.
FR3094211B1 (fr) * 2019-04-01 2023-11-17 Exsymol Sa utilisation cosmétique de composés organo-siliciés
MX2021016024A (es) * 2019-06-28 2022-04-06 Rxw Group Nv Composicion de agua potable y pienso para aves de corral que comprende monometilsilanotriol.
EP4385486A1 (en) * 2022-12-16 2024-06-19 Laboratoires Fill-Med Manufacturing Combination of an organosilicon compound with a crosslinked glycosaminoglucan for preventing and repairing cutaneous ageing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5201M (pt) * 1965-11-05 1967-06-26
FR2158068B1 (pt) * 1971-10-25 1975-02-07 Gueyne Jean
JPS60204708A (ja) * 1984-03-30 1985-10-16 Lion Corp 化粧料用保湿剤
FR2610522B1 (fr) * 1987-02-06 1989-08-18 Gueyne Jean Produit therapeutique a base de derives organiques du silicium
FR2611496B1 (fr) * 1987-03-04 1992-07-03 Gueyne Jean Organo-silicies cosmetiques
JPS6437955A (en) * 1987-08-04 1989-02-08 Kubo Gijutsu Jimusho Kk Deodorant using silicic solution
FR2755968B1 (fr) * 1996-11-19 1998-12-24 Oreal Nouveaux derives silicies de flavones filtres, compositions cosmetiques photoprotectrices les contenant et utilisations
FR2781675B1 (fr) * 1998-07-31 2001-09-07 Berkem Sa Produit bioactif contenant du silicium et des bioflavonoides, ses procedes de preparation et ses utilisations pharmaceutique, dietetique et cosmetique
JP4002760B2 (ja) * 2001-12-21 2007-11-07 株式会社ノエビア 皮膚外用剤

Also Published As

Publication number Publication date
FR2865935A1 (fr) 2005-08-12
CN1917904A (zh) 2007-02-21
BRPI0507182B8 (pt) 2021-07-27
WO2005082421A1 (fr) 2005-09-09
KR101162389B1 (ko) 2012-07-04
MXPA06008898A (es) 2007-02-16
EP1750770A1 (fr) 2007-02-14
PL1750770T3 (pl) 2012-05-31
KR20060130620A (ko) 2006-12-19
EP1750770B1 (fr) 2011-12-21
BRPI0507182B1 (pt) 2019-01-29
PT1750770E (pt) 2011-12-21
ATE537846T1 (de) 2012-01-15
CN1917904B (zh) 2012-03-21
FR2865935B1 (fr) 2006-06-23
ES2377750T3 (es) 2012-03-30

Similar Documents

Publication Publication Date Title
Kim et al. Protective effects of standardized Siegesbeckia glabrescens extract and its active compound kirenol against UVB-induced photoaging through inhibition of MAPK/NF-κB pathways
BR0308196A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
US9770430B2 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
AU758264B2 (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
BRPI0519774A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto
BRPI0510080A (pt) combinações farmacêuticas contendo benzoxazina para tratar doenças respiratórias
BRPI0510084A (pt) benzoxazina para tratamento de doenças do trato respiratório
US9211244B2 (en) Method for anti-skin aging using caffeamide derivative
JP7322094B2 (ja) 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤
BRPI0507182A (pt) uso de compostos organo-silicados para restringir os tecidos conjuntivos lesados
DK2196202T3 (da) Lys-Pro-Thr og Lys-Pro som betændelseshæmmende forbindelser
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
US20210052543A1 (en) Compositions and Methods for Treating Pain with Wogonin
CA2522146A1 (en) Uptake of macromolecules
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
AU2016219617A1 (en) Positively charged water-soluble prodrugs of aspirin
DK155672B (da) Analogifremgangsmaade til fremstilling af aminosyrederivater eller fysiologisk acceptable salte eller optisk aktive isomerer deraf
BR112012020828B1 (pt) preparado farmacêutico que contém miramistina e seu uso
AU2013240456A1 (en) Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections
JP2015500274A (ja) 化学的に修飾して上皮透過および細胞の生物学的利用能を増加させた光力学療法のための組成物
JP2010047535A (ja) 皮膚外用剤
NZ551597A (en) Topical cromolyn formulations
CA3103390A1 (en) Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/737 (2006.01), A61K 31/60 (2006.01), A61K

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO